Consensus GoHealth, Inc.

Equities

GOCO

US38046W2044

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
10.51 USD -4.45% Intraday chart for GoHealth, Inc. +1.64% -21.21%

Evolution of the average Target Price on GoHealth, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a07ed0.ZUKrSGKW5wOgLs0cGgRfejs8cMNsImCKckgnbbLUv9w.JnXuBzDiv2zYGINXQFsuTmNGCoA1UDbEFypsONyaz7I1b8wQJ-ydWpNMjA~dc7decc0f33179abf6bd8a4d53b4f282
RBC Cuts Price Target on GoHealth to $13 From $20, Notes 'Diminished Topline Visibility' in Near Term; Sector Perform Kept MT
RBC Raises PT on GoHealth to $20 From $15 After 'Solid' Q2 Results, Says Encompass Gains Momentum Ahead of Annual Enrollment Period; Sector Perform Kept MT
RBC Raises Price Target on GoHealth to $15 From $14, Maintains Sector Perform Rating MT
Credit Suisse Raises GoHealth's Price Target to $8.50 From $7 After Model Update; Keeps Underperform Rating MT
RBC Cuts Price Target on GoHealth to $14 From $15 After Q4 Miss Amid Negative Revenue Lookback Adjustment; Sector Perform Kept MT
Credit Suisse Adjusts GoHealth's Price Target to $7 From $18.75, Retains Underperform Rating MT
RBC Capital Adjusts GoHealth's Price Target to $1 From $2, Maintains Sector Perform Rating MT
Evercore ISI Adjusts GoHealth's Price Target to $1.75 from $4.50, Keeps In Line Rating MT
Morgan Stanley Adjusts GoHealth Price Target to $1 From $3, Maintains Equalweight Rating MT
RBC Downgrades GoHealth to Sector Perform From Outperform, Slashes Price Target to $2 From $10, Citing 'Sea Change in Operating Backdrop' MT
Truist Securities Downgrades GoHealth to Hold from Buy, Lowers Price Target to $2 From $6 MT
Barclays Adjusts Price Target for GoHealth to $3 From $5, Maintains Equalweight Rating MT
Credit Suisse Downgrades GoHealth to Underperform from Neutral, Says Among Potential M&A Targets; Lowers PT to $3 from $6 MT
BofA Securities Double Downgrades GoHealth to Underperform from Buy, Adjusts Price Target to $3.50 from $7.50; Shares Drop 12% MT
Evercore ISI Lowers Price Target for GoHealth to $4.50 From $7.50, Maintains In-Line Rating MT
Morgan Stanley Adjusts Price Target on GoHealth to $5.50 from $13, Keeps Equalweight Rating MT
Truist Lowers Price Target for GoHealth to $6 From $11, Maintains Buy Rating MT
RBC Cuts Price Target on GoHealth to $10 From $17, Citing Sector Rerating, Maintains Outperform Rating MT
Barclays Downgrades GoHealth to Equalweight from Overweight, Adjusts Price Target to $5 from $10 MT
GOHEALTH : Barclays Adjusts GoHealth's Price Target to $10 from $18, Keeps Overweight Rating MT
GOHEALTH : Credit Suisse Downgrades GoHealth to Neutral from Outperform on Q2 EBITDA Miss, Reduced 2021 EBITDA Outlook; Lowers PT to $10 from $18 MT
GOHEALTH : Receives Cut to Price Target From RBC to $17 From $20, Shares Fall Pre-Bell After Q2 EBITDA Miss; Outperform Kept MT
GOHEALTH : Raymond James Downgrades GoHealth to Market Perform From Outperform MT
GOHEALTH : Evercore ISI Downgrades GoHealth to In-Line From Outperform; Price Target is $9 MT
GoHealth : Refinances $296 Million Term Loan, Nearly Halves Interest Rate to 4% MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.51 USD
Average target price
17.5 USD
Spread / Average Target
+66.51%
High Price Target
22 USD
Spread / Highest target
+109.32%
Low Price Target
13 USD
Spread / Lowest Target
+23.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering GoHealth, Inc.

RBC Capital Markets
Credit Suisse
Morgan Stanley
Evercore ISI
Truist Securities
Barclays
BofA Securities
Raymond James
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings